Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 6;12(6):1702.
doi: 10.3390/nu12061702.

Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases

Alicja Ewa Ratajczak  1 , Anna Maria Rychter  1 , Agnieszka Zawada  1 , Agnieszka Dobrowolska  1 , Iwona Krela-Kaźmierczak  1
Affiliations
Review

Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases

Alicja Ewa Ratajczak et al. Nutrients. .

Abstract

The chronic character of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, results in various complications. One of them is osteoporosis, manifested by low bone mineral density, which leads to an increased risk of fractures. The aetiology of low bone mineral density is multifactorial and includes both diet and nutritional status. Calcium and vitamin D are the most often discussed nutrients with regard to bone mineral density. Moreover, vitamins A, K, C, B12; folic acid; calcium; phosphorus; magnesium; sodium; zinc; copper; and selenium are also involved in the formation of bone mass. Patients suffering from inflammatory bowel diseases frequently consume inadequate amounts of the aforementioned minerals and vitamins or their absorption is disturbed, resulting innutritional deficiency and an increased risk of osteoporosis. Thus, nutritional guidelines for inflammatory bowel disease patients should comprise information concerning the prevention of osteoporosis.

Keywords: bone density; bowel diseases; diet; nutrients; osteoporosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sgambato D., Gimigliano F., De Musis C., Moretti A., Toro G., Ferrante E., Miranda A., De Mauro D., Romano L., Iolascon G., et al. Bone alterations in inflammatory bowel diseases. World J. Clin. Cases. 2019;7:1908–1925. doi: 10.12998/wjcc.v7.i15.1908. - DOI - PMC - PubMed
    1. Miranda-Bautista J., Verdejo C., Díaz-Redondo A., Bretón I., Bellón J.M., Pérez-Valderas M.D., Caballero-Marcos A., de Dios-Lascuevas M., González-Río E., García-Sánchez C., et al. Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain. Ther. Adv. Gastroenterol. 2019;12 doi: 10.1177/1756284819862152. - DOI - PMC - PubMed
    1. Prevention and management of osteoporosis. World Health Organ. Tech. Rep. Ser. 2003;921:1–164. - PubMed
    1. Mirza F., Canalis E. Management of endocrine disease: Secondary osteoporosis: Pathophysiology and management. Eur. J. Endocrinol. 2015;173:R131–R151. doi: 10.1530/EJE-15-0118. - DOI - PMC - PubMed
    1. Krela-Kaźmierczak I., Michalak M., Szymczak-Tomczak A., Łykowska-Szuber L., Stawczyk-Eder K., Waszak K., Kucharski M.A., Dobrowolska A., Eder P. Prevalence of osteoporosis and osteopenia in a population of patients with inflammatory bowel diseases from the Wielkopolska Region. Pol. Arch. Intern. Med. 2018;128:447–454. doi: 10.20452/pamw.4292. - DOI - PubMed